| Global prevalence of type 2 diabetes over the next ten years (2018-2028) AB Kaiser, N Zhang, WVAN Der Pluijm Diabetes 67 (Supplement_1), 2018 | 277 | 2018 |
| Global epidemiology of amyloid light-chain amyloidosis N Kumar, NJ Zhang, D Cherepanov, D Romanus, M Hughes, DV Faller Orphanet Journal of Rare Diseases 17 (1), 278, 2022 | 44 | 2022 |
| Global prevalence of type 2 diabetes over the next ten years (2018-2028) A Bradshaw Kaiser, N Zhang, W Van Der Pluijm Diabetes 67 (Supplement_1), 202-LB, 2018 | 15 | 2018 |
| Impact of STK11 mutation on first-line immune checkpoint inhibitor (ICI) outcomes in a real-world KRAS G12C mutant lung adenocarcinoma cohort. RS Heist, J Yu, EY Donderici, N Zhang, CR Espenschied, K Lang, ... Journal of Clinical Oncology 39 (15_suppl), 9106-9106, 2021 | 11 | 2021 |
| Comprehensive genomic profiling of circulating tumor DNA in patients with previously treated metastatic colorectal cancer: analysis of a real-world healthcare claims database Y Nakamura, S Olsen, N Zhang, J Liao, T Yoshino Current Oncology 29 (5), 3433-3448, 2022 | 6 | 2022 |
| Clinical utility of microsatellite instability (MSI-H) identified on liquid biopsy in advanced gastrointestinal cancers (aGI). PM Kasi, SJ Klempner, JS Starr, A Shergill, LA Bucheit, C Weipert, J Liao, ... Journal of Clinical Oncology 40 (4_suppl), 56-56, 2022 | 6 | 2022 |
| Global Prevalence of Type 2 Diabetes over the Next Ten Years (2018–2028)[LB.]. Diabetes.; 67 Supplement 1: 202 AB Kaiser, N Zhang, WV Der Pluijm, AB Kaiser, N Zhang, ... | 5 | 2018 |
| MA07. 03 Real-world landscape of EGFR C797X mutation as a resistance mechanism to osimertinib in non-small cell lung cancer SS Ramalingam, N Zhang, J Yu, C Espenschied, T Green, J Infantine, ... Journal of Thoracic Oncology 17 (9), S67-S68, 2022 | 4 | 2022 |
| Real-world landscape of EGFR C797X mutation as a resistance mechanism to osimertinib in NSCLC SS Ramalingam, N Zhang, J Yu, C Espenschied, T Green, J Infantine, ... International Association for the Study of Lung Cancer 2022 World Conference …, 2022 | 4 | 2022 |
| Real-world treatment patterns in patients with HER2-amplified metastatic colorectal cancer: a clinical-genomic database study JH Strickler, LI Hsu, P Wright, M Stecher, MF Siadak, ... Journal of the National Comprehensive Cancer Network 21 (8), 805-812. e1, 2023 | 2 | 2023 |
| Real-world assessment of AR-LBD mutations in metastatic castration-resistant prostate cancer ES Antonarakis, N Zhang, J Saha, L Nevalaita, SA Shell, C Garratt, ... J. Clin. Oncol 41 (204), 10.1200, 2023 | 2 | 2023 |
| 439P Characteristics and treatment patterns among patients with HER2-amplified advanced/metastatic colorectal cancer (mCRC): A clinical-genomic database study JH Strickler, LI Hsu, K DeBusk, P Wright, M Stecher, M Siadak, ... Annals of Oncology 32, S554, 2021 | 2 | 2021 |
| Estimating the Global Epidemiology of Amyloid Light-Chain Amyloidosis With an Incidence-to-Prevalence Model N Zhang, D Cherepanov, D Romanus, N Kumar, M Hughes, DV Faller Clinical Lymphoma, Myeloma and Leukemia 19 (10), e339, 2019 | 2 | 2019 |
| CDK4/6 Inhibitor Efficacy in ESR1-Mutant Metastatic Breast Cancer MR Lloyd, JO Brett, A Carmeli, CM Weipert, N Zhang, J Yu, L Bucheit, ... NEJM evidence 3 (5), EVIDoa2300231, 2024 | 1 | 2024 |
| Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes PM Kasi, LA Bucheit, J Liao, J Starr, P Barata, SJ Klempner, D Gandara, ... JCO Precision Oncology 7, e2300118, 2023 | 1 | 2023 |
| Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA … SA Wander, CM Weipert, J Liao, A Safonov, N Zhang, A Bardia, P Razavi Journal of Clinical Oncology 41 (16_suppl), 1081-1081, 2023 | 1 | 2023 |
| Abstract LB123: Poorer outcomes in EGFR L858R-driven NSCLC treated with osimertinib may be addressed with novel combination of BLU-945 and osimertinib YY Elamin, T Rouskin-Faust, N Zhang, T Green, A Dhande, BG Mar, ... Cancer research 83 (8_Supplement), LB123-LB123, 2023 | 1 | 2023 |
| Abstract P4-01-18: Real-world second-line treatment patterns and associated clinical outcomes for 2795 patients with advanced HR+ HER2-breast cancer treated with first-line … KK Clifton, SA Wander, C Ma, AA Davis, C Weipert, N Zhang, L Bucheit Cancer Research 83 (5_Supplement), P4-01-18-P4-01-18, 2023 | 1 | 2023 |
| Use of circulating tumor DNA (ctDNA) for early assessment of treatment response in patients with advanced colorectal cancer (aCRC): A real-world (RW) analysis. PM Kasi, C Weipert, T Nguyen, J Liao, N Zhang, S Forbes, S Gordon, ... Journal of Clinical Oncology 41 (4_suppl), 246-246, 2023 | 1 | 2023 |
| Use of real-world data (RWD) to assess the utility of cell-free circulating tumor DNA (cfDNA) in identifying resistance to early treatment in advanced breast cancer (aBC). SA Wander, C Weipert, J Liao, N Zhang, P Razavi Journal of Clinical Oncology 40 (16_suppl), 1011-1011, 2022 | 1 | 2022 |
